The Investor
19 Nov 2026, 16:44
Merck Partners With Isomorphic Labs to Use AI in Oncology Drug Discovery
Merck (NYSE: MRK) entered a strategic research collaboration with Isomorphic Labs to discover small-molecule drug candidates against an oncology target, combining Merck’s proprietary data and drug-development expertise with Isomorphic Labs’ AI-based drug design platform.
Under the agreement, Isomorphic Labs will use its IsoDDE drug design engine and selected Merck data sets to make in silico predictions and design potential molecules. Merck will take responsibility for preclinical and clinical development, manufacturing and commercialization of any products that emerge from the collaboration.
Isomorphic Labs will receive an upfront payment and may earn additional research, development, regulatory and commercial milestone payments, as well as tiered royalties on future net sales. The company also has an option to co-fund development in exchange for higher royalties. Financial terms were not disclosed.
The partnership expands Merck’s use of AI in early-stage drug discovery and could help shorten molecule-design cycles by combining computational modeling with proprietary experimental data. However, the collaboration remains at the research stage, so any financial contribution would depend on successful candidate discovery, development and regulatory progress.
Merck (NYSE: MRK) entered a strategic research collaboration with Isomorphic Labs to discover small-molecule drug candidates against an oncology target, combining Merck’s proprietary data and drug-development expertise with Isomorphic Labs’ AI-based drug design platform.
Under the agreement, Isomorphic Labs will use its IsoDDE drug design engine and selected Merck data sets to make in silico predictions and design potential molecules. Merck will take responsibility for preclinical and clinical development, manufacturing and commercialization of any products that emerge from the collaboration.
Isomorphic Labs will receive an upfront payment and may earn additional research, development, regulatory and commercial milestone payments, as well as tiered royalties on future net sales. The company also has an option to co-fund development in exchange for higher royalties. Financial terms were not disclosed.
The partnership expands Merck’s use of AI in early-stage drug discovery and could help shorten molecule-design cycles by combining computational modeling with proprietary experimental data. However, the collaboration remains at the research stage, so any financial contribution would depend on successful candidate discovery, development and regulatory progress.